Patient-reported side effects of intradetrusor botulinum toxin type A for idiopathic overactive bladder syndrome

Urologia Internationalis

Volumn 86, Issue 1, 2011, Pages 68-72

  Bauer, Ricarda M ^a   Gratzke, Christian ^a   Roosen, Alexander ^a   Hocaoglu, Yasmin ^a   Mayer, Margit E ^a   Buchner, Alexander ^a   Stief, Christian G ^a   May, Florian ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Botox ; Botulinum toxin; Botulinum toxin side effects; Dysport ; Idiopathic overactive bladder; Intradetrusor injection

Indexed keywords

ANTIBIOTIC AGENT; BOTULINUM TOXIN A;

ADULT; AGED; ARM WEAKNESS; ARTICLE; BLADDER CATHETERIZATION; CLINICAL TRIAL; DETRUSOR MUSCLE; DYSPHAGIA; EYELID DISEASE; EYELID WEAKNESS; FEMALE; FLUID INTAKE; FOLLOW UP; HEMATURIA; HUMAN; IDIOPATHIC DISEASE; INTERMITTENT CATHETERIZATION; LIMB WEAKNESS; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; OPEN STUDY; OVERACTIVE BLADDER; PATIENT SATISFACTION; POSTOPERATIVE INFECTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT INFECTION; RESIDUAL URINE; SELF REPORT; SPEECH DISORDER; TORSO WEAKNESS; URINARY TRACT INFECTION; URINE RETENTION; VISUAL IMPAIRMENT; WEAKNESS; WHOLE BODY WEAKNESS; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXINS, TYPE A; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 79951813454     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000316080     Document Type: Article

References (24)

1. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P: Population- based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306-1314.
2. Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I: The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008; 101: 1388-1395. (Pubitemid 351623990)
3. Irwin DE, Mungapen L, Milsom I, Kopp Z, Reeves P, Kelleher C: The economic impact of overactive bladder syndrome in six western countries. BJU Int 2009; 103: 202-209.
4. Andersson KE, Chapple CR, Cardozo L, Cruz F, Hashim H, Michel MC, Tannenbaum C, Wein AJ: Pharmacological treatment of overactive bladder: Report from the international consultation on incontinence. Curr Opin Urol 2009; 19: 380-394.
5. Flynn MK, Amundsen CL, Perevich M, Liu F, Webster GD: Outcome of a randomized, double-blind, placebo-controlled trial of botulinum a toxin for refractory overactive bladder. J Urol 2009; 181: 2608-2615.
6. Schmid DM, Sauermann P, Werner M, Schuessler B, Blick N, Muentener M, Strebel RT, Perucchini D, Scheiner D, Schaer G, John H, Reitz A, Hauri D, Schurch B: Experience with 100 cases treated with botulinum A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 2006; 176: 177-185. (Pubitemid 43815416)
7. Schurch B: Botulinum toxin for the management of bladder dysfunction. Drugs 2006; 66: 1301-1318.
8. Leong RK, De Wachter SG, van Kerrebroeck PE: Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review. Urol Int 2010; 84: 245-253.
9. Stoehrer M, Wolff A, Kramer G, Steiner R, Lmochner-Ernst D, Leuth D, Steude U, Ruebben H: Treatment of neurogenic detrusor overactivity with botulinum toxin A: the first seven years. Urol Int 2009; 83: 379-385.
10. Cohen BL, Barboglio P, Rodriguez D, Gousse AE: Preliminary results of a dose-finding study for botulinum toxin A in patients with idiopathic overactive bladder: 100 versus 150 units. Neurourol Urodyn 2009; 28: 205-208.
11. Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, Barber MD, Menefee S, Schaffer J, Weber AM, Wei J: Refractory idiopathic urge urinary incontinence and botulinum a injection. J Urol 2008; 180: 217-222.
12. Chancellor MB: Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery. Int Urol Nephrol 2010; 42:383-391.
13. Kuo HC: Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin A for idiopathic detrusor overactivity. J Urol 2007; 178: 1359-1363.
14. Mohanty NK, Nayak RL, Alam M, Arora RP: Role of botulinum toxin A in management of refractory idiopathic detrusor overactive bladder: single-center experience. Indian J Urol 2008; 24: 182-185.
15. Sahai A, Khan MS, Dasgupta P: Efficacy of botulinum toxin A for treating idiopathic detrusor overactivity: results from a singlecenter, randomized, double-blind, placebocontrolled trial. J Urol 2007; 177: 2231-2236. (Pubitemid 46726400)
16. Jeffery S, Fynes M, Lee F, Wang K, Williams L, Morley R: Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int 2007; 100: 1302-1306. (Pubitemid 350043916)
17. Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P: A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum A toxin. J Urol 2005; 174: 984-989. (Pubitemid 41140656)
18. Mehnert U, Schurch B: Botulinum toxin in non-neurogenic bladder dysfunction (in German). Urologe 2009; 48: 233-244.
19. Shaban AM, Drake MJ: Botulinum toxin treatment for overactive bladder: risk of urinary retention. Curr Urol Rep 2008; 9: 445-451.
20. Kalsi V, Popat RB, Apostolidis A, Kavia R, Odeyemi IA, Dakin HA, Warner J, Elneil S, Fowler CJ, Dasgupta P: Cost-consequence analysis evaluating the use of botulinum neurotoxin A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 2006; 49: 519-527. (Pubitemid 43259563)
21. Smith CP, Nishiguchi J, O'Leary M, Yoshimura N, Chancellor MB: Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 2005; 65: 37-41. (Pubitemid 40169601)
22. Eleopra R, Tugnoli V, Caniatti L, De Grandis D: Botulinum toxin treatment in the facial muscles of humans: evidence of an action in untreated near muscles by peripheral local diffusion. Neurology 1996; 46: 1158-1160. (Pubitemid 26134671)
23. Garner CG, Straube A, Witt TN, Gasser T, Oertel WH: Time course of distant effects of local injections of botulinum toxin. Mov Disord 1993; 8: 33-37. (Pubitemid 23039227)
24. Lange DJ, Brin MF, Fahn S, Lovelace RE: Distant effects of locally injected botulinum toxin: Incidence and course. Adv Neurol 1988; 50: 609-613.